Gritstone Oncology, Inc. (GRTS)
| Market Cap | 580.19M |
| Revenue (ttm) | 44.82M |
| Net Income (ttm) | -70.44M |
| Shares Out | 76.75M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 672,656 |
| Open | 8.89 |
| Previous Close | 9.03 |
| Day's Range | 8.53 - 9.00 |
| 52-Week Range | 2.54 - 35.20 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 28.43 (+218.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, incl...
Financial Performance
In 2020, GRTS's revenue was $4.04 million, a decrease of -7.51% compared to the previous year's $4.37 million. Losses were -$105.31 million, 11.5% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 28.43, which is an increase of 218.37% from the latest price.
News
Does This Biotech Have the Secret to Conquering Covid Variants?
The company uses mRNA technology -- with a new twist.
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster ...
GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterologous p...
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neo...
EMERYVILLE, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapie...
Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO...
Webcast today, September 17 at 1:30pm ET
Gritstone Announces Private Placement Financing of $55.0 Million
EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies...
3 Explosive Biotech Stocks That Could 10X in 10 Years
They're leaders in therapeutic areas with massive growth potential.
3 Monster Stocks in the Making to Buy Right Now
Their growth prospects are massive.
Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021
EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...
Gritstone bio Inc. (GRTS) is a Great Momentum Stock: Should You Buy?
Does Gritstone bio Inc. (GRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gritstone Announces Presentations at Two Investor Conferences in September
EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
Gritsone Bio Secures CEPI Funding For Its Differentiated COVID-19 Vaccine Candidate
Gritstone bio Inc (NASDAQ: GRTS) has entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI). The funding will support Gritstone's COVID-1...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunothe...
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Lags Revenue Estimates
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 37.74% and -5.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Reports Second Quarter 2021 Financial Results and Business Update
EMERYVILLE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies,...
Will Gritstone bio Inc. (GRTS) Report Negative Q2 Earnings? What You Should Know
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer
EMERYVILLE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies,...
3 Top Biotech Picks for June
Coronavirus players may deliver strong returns well into the future.
Gritstone Announces Changes to Its Board of Directors
Drs. Naiyer A. Rizvi and Shefali Agarwal Join the Board Drs. Naiyer A. Rizvi and Shefali Agarwal Join the Board
Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates
Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Reports First Quarter 2021 Financial Results and Business Highlights
EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, ...
Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immun...
3 Top Coronavirus Stocks to Buy Right Now
Major gains may be on the horizon.